Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 14803.203 | 0.2688 | -0.2025 | 1.4290 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14803.203 | 0.2028 | -0.3453 | 1.4290 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14803.203 | 0.2028 | -0.3453 | 1.4290 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14803.203 | 0.1666 | -0.4294 | 1.4290 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14803.203 | 0.1666 | -0.4294 | 1.4290 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14803.203 | 0.1643 | -0.4349 | 1.4290 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14803.203 | 0.1643 | -0.4349 | 1.4290 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15335.203 | 0.9986 | 0.9966 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.000171 | uM | 15335.203 | 0.9986 | 0.9966 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 15335.203 | 0.9799 | 0.9509 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.000853 | uM | 15335.203 | 0.9799 | 0.9509 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 15335.203 | 0.9081 | 0.7774 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.00427 | uM | 15335.203 | 0.9081 | 0.7774 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 15335.203 | 0.6798 | 0.2470 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.0213 | uM | 15335.203 | 0.6798 | 0.2470 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 15335.203 | 0.2997 | -0.5425 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.107 | uM | 15335.203 | 0.2997 | -0.5425 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 15335.203 | 0.1370 | -0.8246 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 0.533 | uM | 15335.203 | 0.1370 | -0.8246 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 15335.203 | 0.0929 | -0.8908 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 15335.203 | 0.0929 | -0.8908 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 15335.203 | 0.0570 | -0.9399 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 15335.203 | 0.0570 | -0.9399 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15335.203 | 0.0428 | -0.9577 | 0.8170 | |
| SUM225CWN | HER2amp | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15335.203 | 0.0428 | -0.9577 | 0.8170 |